Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Toxicity
67%
Solid Malignant Neoplasm
67%
Maximum Tolerated Dose
52%
Diseases
40%
Neoplasm
40%
Adverse Event
38%
Alisertib
30%
Fatigue
27%
Tolerability
24%
Paclitaxel
22%
Antitumor Activity
22%
Pharmacodynamics
20%
Malignant Neoplasm
17%
Vorinostat
17%
Neutropenia
17%
Drug
16%
Cabazitaxel
15%
Hydroxychloroquine
13%
Chemotherapy
12%
Thrombocytopenia
11%
Progression Free Survival
11%
Diarrhea
11%
Moderate Hepatic Impairment
11%
Overall Survival
10%
Liver Dysfunction
10%
Spartalizumab
10%
Bortezomib
10%
Sonidegib
10%
Lurbinectedin
10%
Placebo
9%
Vasculotropin
9%
Severe Hepatic Impairment
9%
Metastatic Colorectal Cancer
9%
Mild Hepatic Impairment
9%
Advanced Cancer
9%
Phase I Trials
9%
Anemia
8%
Docetaxel
8%
Febrile Neutropenia
8%
Clinical Trial
7%
Monotherapy
7%
Peptide
7%
Sorafenib
7%
Pembrolizumab
7%
Nausea
7%
Antibody
7%
Erlotinib
7%
Capsule
7%
Taxane
7%
Medicine and Dentistry
Patient
61%
Therapeutic Procedure
17%
Vorinostat
12%
Arm
12%
Inpatient
10%
Lurbinectedin
10%
Diseases
10%
Hydroxychloroquine
8%
Progression Free Survival
8%
Overall Survival
8%
Combination Therapy
7%
Malignant Neoplasm
7%
Autophagy
7%
Liver Dysfunction
7%
Solid Malignant Neoplasm
6%
Adverse Event
6%
Small Cell Lung Cancer
5%
Regorafenib
5%
Prostate Cancer
5%
Pharmacokinetics
5%
Antineoplastic Activity
5%
Ewing Sarcoma
5%
Mipsagargin
5%
Osteoclast Differentiation Factor
5%
Metabolic Syndrome
5%
Diabetes Mellitus
5%
Androgen Deprivation Therapy
5%
Man
5%
Glycon
5%
